NCT07249372

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

A Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	DRP-104	DRP-104 will be administered subcutaneously (subQ) at a dose of 145mg twice a week (BIW) on a continuous schedule. Once the first dose is administered, the second weekly dose is to be administered 3 days after the first dose with a four-day rest period before the next week of therapy (example, Monday/Thursday or Tuesday/Friday).

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-10-31
• Completion: 2028-10-31
• First posted: 2025-11-25
• Last updated: 2025-11-25

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study